After peptide stimulation in the presence of anti-IL10 blockade, the frequency of MSLN-specific CD8+ T cells was increased in PBMC of 2 out of 7 patients with pancreatic cancer.. This evidence concerns the gene CD8A and familial pancreatic carcinoma.